Evidence map›Paper›PMID 35640675›Full record

ArticleThe American journal of pathology2022

Premortem Skin Biopsy Assessing Microthrombi, Interferon Type I Antiviral and Regulatory Proteins, and Complement Deposition Correlates with Coronavirus Disease 2019 Clinical Stage.

Jeffrey Laurence, Gerard Nuovo, Sabrina E Racine-Brzostek, Madhav Seshadri, Sonia Elhadad, A Neil Crowson, J Justin Mulvey, Joanna Harp, Jasimuddin Ahamed, Cynthia Magro

Open access · bronzeAbstract read
In one paragraph

Article in The American journal of pathology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
3.0field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Observational
  4. Article
  5. Review
  6. Article
  7. Review
  8. Microvascular Thrombosis as a Critical Factor in Severe COVID-19.International journal of molecular sciences · 2023
    Article
  9. Article
  10. Review
  11. Microvascular significance of TGF-β axis activation in COVID-19.Frontiers in cardiovascular medicine · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Jeffrey LaurenceDivision of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medicine, New York, New York. Electronic address: jlaurenc@med.cornell.edu.
Gerard NuovoThe Ohio State University Comprehensive Cancer Center, Columbus, Ohio; Discovery Life Sciences, Inc., Powell, Ohio.
Sabrina E Racine-BrzostekDepartment of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, New York.
Madhav SeshadriDivision of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medicine, New York, New York.
Sonia ElhadadDivision of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medicine, New York, New York.
A Neil CrowsonDepartment of Pathology, Regional Medical Laboratories, Tulsa, Oklahoma.
J Justin MulveyDepartment of Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Joanna HarpDepartment of Dermatology, Weill Cornell Medicine, New York, New York.
Jasimuddin AhamedCardiovascular Biology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma.
Cynthia MagroDepartment of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, New York.
Cornell University · USLife Sciences Discovery Fund · USMemorial Sloan Kettering Cancer Center · USOklahoma Medical Research Foundation · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
The Role of TGF-beta Activation and Signaling in Aortic Stenosis ProgressionR01HL148123 · NHLBI · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI Jasimuddin Ahamed · 2020 to 2026
$2.9M
NCI NIH HHS P30 CA008748NHLBI NIH HHS R01 HL148123
6 · The paper itself

Abstract

Apart from autopsy, tissue correlates of coronavirus disease 2019 (COVID-19) clinical stage are lacking. In the current study, cutaneous punch biopsy specimens of 15 individuals with severe/critical COVID-19 and six with mild/moderate COVID-19 were examined. Evidence for arterial and venous microthrombi, deposition of C5b-9 and MASP2 (representative of alternative and lectin complement pathways, respectively), and differential expression of interferon type I-driven antiviral protein MxA (myxovirus resistance A) versus SIN3A, a promoter of interferon type I-based proinflammatory signaling, were assessed. Control subjects included nine patients with sepsis-related acute respiratory distress syndrome (ARDS) and/or acute kidney injury (AKI) pre-COVID-19. Microthrombi were detected in 13 (87%) of 15 patients with severe/critical COVID-19 versus zero of six patients with mild/moderate COVID-19 (P < 0.001) and none of the nine patients with pre-COVID-19 ARDS/AKI (P < 0.001). Cells lining the microvasculature staining for spike protein of severe acute respiratory syndrome coronavirus 2, the etiologic agent of COVID-19, also expressed tissue factor. C5b-9 deposition occurred in 13 (87%) of 15 patients with severe/critical COVID-19 versus zero of six patients with mild/moderate COVID-19 (P < 0.001) and none of the nine patients with pre-COVID-19 ARDS/AKI (P < 0.001). MASP2 deposition was also restricted to severe/critical COVID-19 cases. MxA expression occurred in all six mild/moderate versus two (15%) of 13 severe/critical cases (P < 0.001) of COVID-19. In contrast, SIN3A was restricted to severe/critical COVID-19 cases co-localizing with severe acute respiratory syndrome coronavirus 2 spike protein. SIN3A was also elevated in plasma of patients with severe/critical COVID-19 versus control subjects (P ≤ 0.02). In conclusion, the study identified premortem tissue correlates of COVID-19 clinical stage using skin. If validated in a longitudinal cohort, this approach could identify individuals at risk for disease progression and enable targeted interventions.

Indexed as

Acute Kidney InjuryCOVID-19Interferon Type IRespiratory Distress SyndromeThrombosisAntiviral AgentsBiopsyComplement Membrane Attack ComplexHumansMannose-Binding Protein-Associated Serine ProteasesSpike Glycoprotein, CoronavirusAntiviral AgentsComplement Membrane Attack ComplexInterferon Type IMannose-Binding Protein-Associated Serine ProteasesMASP2 protein, humanSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2

Identifiers

PMID35640675
PMCPMC9144849
OpenAlexW4281919555

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.